Phase 1, Randomized, Double-Blind, Third-Party Open Placebo-Controlled, Dose Escalating Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single And Multiple Intravenous And Subcutaneous Doses Of PF-06823859 In Healthy Subjects

Trial Profile

Phase 1, Randomized, Double-Blind, Third-Party Open Placebo-Controlled, Dose Escalating Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single And Multiple Intravenous And Subcutaneous Doses Of PF-06823859 In Healthy Subjects

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Aug 2017

At a glance

  • Drugs PF 6823859 (Primary) ; PF 6823859 (Primary)
  • Indications Lupus vulgaris
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 24 Mar 2017 Status changed from recruiting to active, no longer recruiting.
    • 14 Feb 2017 Planned number of patients changed from 76 to 64.
    • 14 Feb 2017 Planned End Date changed from 1 Jul 2017 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top